We are live on ! Find out more
FP

Flagship Pioneering Portfolio holdings

AUM $1.54B
1-Year Est. Return 86.39%
This Fund
S&P 500
This Quarter Est. Return
-18.07%
1 Year Est. Return
+86.39%
3 Year Est. Return
-13.28%
5 Year Est. Return
-50.7%
10 Year Est. Return
+414.55%
AUM
$394M
AUM Growth
+$95.3M
Cap. Flow
+$192M
Cap. Flow %
48.62%
Top 10 Hldgs %
100%
Holding
6
New
2
Increased
–
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
DNLI icon
Denali Therapeutics
DNLI
+$160M
2
QTRX icon
Quanterix
QTRX
+$39.6M

Top Sells

Rank Stock Value
1
TTOO
T2 Biosystems, Inc
TTOO
+$8.19M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNLI icon
1
Denali Therapeutics
DNLI
$3.26B
$139M 35.37%
+8,918,749
New +$160M
MCRB icon
2
Seres Therapeutics
MCRB
$46.2M
$129M 32.61%
634,144
– –
EDIT icon
3
Editas Medicine
EDIT
$404M
$51.5M 13.05%
1,674,435
– –
QTRX icon
4
Quanterix
QTRX
$129M
$43.6M 11.06%
+2,030,495
New +$39.6M
SYRS
5
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$31.2M 7.91%
320,444
– –
TTOO
6
DELISTED
T2 Biosystems, Inc
TTOO
– –
-390
Closed -$8.19M

Similar funds

SPC
Stony Point Capital New York $1.54B AUM 54.05% 1-Year Est. Return
AWC
Abundance Wealth Counselors State College, Pennsylvania $1.54B AUM 31.07% 1-Year Est. Return
SMC
Smith, Moore & Co Clayton, Missouri $1.54B AUM 24.82% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.54B AUM 30.95% 1-Year Est. Return
BOF
Bank of Finland Helsinki, Finland $1.54B AUM 15.84% 1-Year Est. Return
KCM
Kanawha Capital Management Richmond, Virginia $1.54B AUM 21.3% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.54B AUM 27.61% 1-Year Est. Return
HCM
Hollencrest Capital Management Newport Beach, California $1.54B AUM 30.1% 1-Year Est. Return

Flagship Pioneering's Q4 2017 Portfolio in Review

As of Q4 2017, Flagship Pioneering held 6 positions worth $394M, up 32% from $299M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Flagship Pioneering deployed $192M of net new capital in Q4 2017, opening 2 new positions. Its largest new stake was Denali Therapeutics: 8,918,749 shares worth $139M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the most notable exit was T2 Biosystems, Inc, an estimated $8.19M sold.

  • Flagship Pioneering's largest Q4 2017 buy was Denali Therapeutics: 8,918,749 shares worth $139M.
  • Flagship Pioneering fully exited T2 Biosystems, Inc in Q4 2017, selling an estimated $8.19M.
  • Flagship Pioneering's ten largest holdings make up 100% of its $394M portfolio in Q4 2017.
  • Flagship Pioneering opened 2 new positions and closed 1 in Q4 2017.
  • Flagship Pioneering's portfolio value rose 32% quarter-over-quarter to $394M.

Based on Flagship Pioneering's 13F filing for Q4 2017, filed 14 Feb 2018.